Huntleigh Advisors, Inc. Oncolytics Biotech Inc Transaction History
Huntleigh Advisors, Inc.
- $592 Billion
- Q4 2025
A detailed history of Huntleigh Advisors, Inc. transactions in Oncolytics Biotech Inc stock. As of the latest transaction made, Huntleigh Advisors, Inc. holds 13,000 shares of ONCY stock, worth $13,650. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,000Holding current value
$13,650% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ONCY
# of Institutions
59Shares Held
2.83MCall Options Held
0Put Options Held
0-
Morgan Stanley New York, NY383KShares$402,5130.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il382KShares$401,1530.0% of portfolio
-
Marshall Wace, LLP London, X0324KShares$340,1810.0% of portfolio
-
Seeds Investor LLC New York, NY258KShares$271,2210.04% of portfolio
-
Goldman Sachs Group Inc New York, NY209KShares$219,1320.0% of portfolio
About ONCOLYTICS BIOTECH INC
- Ticker ONCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 57,867,400
- Market Cap $60.8M
- Description
- Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a...